Shares in Stratagene fell 3.1 percent for the trading week ended Tuesday. The decline followed last week's drop of 23.3 percent, but the reasons for its fall remain unclear. Stratagene's shares finished Tuesday at $7.16 hovering above a 52-week low of $6.42 reached last September. Bruker led gainers for the week with a 6.3-percent rise.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.